Home4DX • ASX
add
4DMedical Ltd
Nakaraang pagsara
$0.28
Sakop ng araw
$0.28 - $0.29
Sakop ng taon
$0.23 - $0.72
Market cap
128.37M AUD
Average na Volume
948.52K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(AUD) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 1.45M | 265.33% |
Gastos sa pagpapatakbo | 13.10M | 7.86% |
Net na kita | -9.58M | -22.82% |
Net profit margin | -662.04 | 66.38% |
Kita sa bawat share | — | — |
EBITDA | -11.23M | -1.87% |
Aktuwal na % ng binabayarang buwis | -0.04% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(AUD) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 15.95M | -66.68% |
Kabuuang asset | 102.01M | -29.03% |
Kabuuang sagutin | 42.15M | -19.87% |
Kabuuang equity | 59.86M | — |
Natitirang share | 413.32M | — |
Presyo para makapag-book | 2.04 | — |
Return on assets | -28.80% | — |
Return on capital | -45.42% | — |
Cash Flow
Net change in cash
(AUD) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | -9.58M | -22.82% |
Cash mula sa mga operasyon | -7.07M | 4.01% |
Cash mula sa pag-invest | -422.55K | 97.85% |
Cash mula sa financing | 170.01K | -98.95% |
Net change in cash | -7.33M | 32.46% |
Malayang cash flow | -6.17M | 4.49% |
Tungkol
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Itinatag
2013
Website
Mga Empleyado
145